H M Adnan Hameed
Overview
Explore the profile of H M Adnan Hameed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fang C, Zhang H, He J, Tian X, Zeng S, Han X, et al.
Microbiol Spectr
. 2025 Feb;
:e0228924.
PMID: 40009796
The escalating threat of mycobacterial infectious diseases, particularly those caused by nontuberculous mycobacteria (NTM), poses a serious challenge to public health. Linezolid (LZD), an oxazolidinone antimicrobial, exhibits potent activity against...
2.
Ding J, Hameed H, Long L, Zhang J, Fang C, Tian X, et al.
J Antimicrob Chemother
. 2025 Jan;
80(3):746-751.
PMID: 39871738
Objectives: Amikacin is crucial for treating Mycobacterium abscessus (Mab) infections, with resistance primarily attributed to rrs gene mutations. The correlation between specific mutations and amikacin susceptibility, along with the associated...
3.
Tian X, Gao Y, Li C, Ma W, Zhang J, Ju Y, et al.
Front Pharmacol
. 2025 Jan;
15():1400436.
PMID: 39830329
The efficacy of many compounds against is often limited when administered via conventional oral or injection routes due to suboptimal pharmacokinetic characteristics. Inhalation-based delivery methods have been investigated to achieve...
4.
Zhang J, Ju Y, Li L, Hameed H, Yusuf B, Gao Y, et al.
Int J Antimicrob Agents
. 2025 Jan;
65(2):107442.
PMID: 39761758
Mycobacterium abscessus (Mab) poses serious therapeutic challenges, largely due to its intrinsic resistance to many antibiotics. The development of targeted therapeutic strategies necessitates the identification of bacterial factors that contribute...
5.
He J, Gao Y, Wang J, Hameed H, Wang S, Fang C, et al.
mLife
. 2024 Oct;
3(3):459-470.
PMID: 39359678
Treatment of (Mab) infections is very challenging due to its intrinsic resistance to most available drugs. Therefore, it is crucial to discover novel anti-Mab drugs. In this study, we explored...
6.
Yusuf B, Wang S, Alam M, Zhang J, Liu Z, Lu Z, et al.
Microbiol Spectr
. 2024 Aug;
12(10):e0397423.
PMID: 39162545
Importance: This study reports the role of a putative fadD (MAB_1915) in innate resistance to multiple drugs by , hence identifying MAB_1915 as a valuable target and providing a baseline...
7.
Yu W, Ju Y, Han X, Tian X, Ding J, Wang S, et al.
Antimicrob Agents Chemother
. 2024 May;
68(6):e0012424.
PMID: 38690893
As an obligate aerobe, relies on its branched electron transport chain (ETC) for energy production through oxidative phosphorylation. Regimens targeting ETC exhibit promising potential to enhance bactericidal activity against and...
8.
Han X, Gao Y, Zhou B, Hameed H, Fang C, Ju Y, et al.
ACS Infect Dis
. 2024 Mar;
10(4):1201-1211.
PMID: 38457660
Tuberculosis (TB) is the leading infectious disease caused by and the second-most contagious killer after COVID-19. The emergence of drug-resistant TB has caused a great need to identify and develop...
9.
Islam M, Alam M, Liu Z, Khatun M, Yusuf B, Hameed H, et al.
Front Med (Lausanne)
. 2024 Jan;
10:1304857.
PMID: 38274444
Clofazimine (CFZ) and bedaquiline (BDQ) are currently used for the treatment of multidrug-resistant (MDR) () strains. In recent years, adding CFZ and BDQ to tuberculosis (TB) drug regimens against MDR...
10.
Khan Z, Zhu Y, Guan P, Peng J, Su B, Ma S, et al.
J Thorac Dis
. 2023 Nov;
15(10):5494-5506.
PMID: 37969306
Background: Tuberculosis (TB) remains a significant global health emergency caused by (Mtb). The epidemiology, transmission, genotypes, mutational patterns, and clinical consequences of TB have been extensively studied worldwide, however, there...